ATN ASTROCYTES TO NEURONS

Serial Number 97227503
Registration 8033032
700

Registration Progress

Application Filed
Jan 19, 2022
Under Examination
Apr 11, 2023
Approved for Publication
Feb 14, 2023
Published for Opposition
Feb 14, 2023
Registered
Nov 18, 2025

Trademark Image

ATN ASTROCYTES TO NEURONS

Basic Information

Serial Number
97227503
Registration Number
8033032
Filing Date
January 19, 2022
Registration Date
November 18, 2025
Published for Opposition
February 14, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Nov 18, 2025
Registration
Registered
Classes
042

Rights Holder

NeuExcell Therapeutics Inc.

03
Address
Suite 242
401 N. Broad St.
Philadelphia, PA 19108

Ownership History

NeuExcell Therapeutics Inc.

Original Applicant
03
Philadelphia, PA

NeuExcell Therapeutics Inc.

Owner at Publication
03
Philadelphia, PA

NeuExcell Therapeutics Inc.

Original Registrant
03
Philadelphia, PA

Legal Representation

Attorney
Lawrence M. Green

USPTO Deadlines

Next Deadline
2132 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20251118)
Due Date
November 18, 2031
Grace Period Ends
May 18, 2032
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

39 events
Date Code Type Description Documents
Nov 18, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Nov 18, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Oct 30, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Oct 30, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Sep 23, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Apr 29, 2025 IUAF S USE AMENDMENT FILED Loading...
Sep 23, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Apr 29, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Apr 8, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 7, 2025 EX4G S SOU EXTENSION 4 GRANTED Loading...
Apr 7, 2025 EXT4 S SOU EXTENSION 4 FILED Loading...
Apr 7, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 28, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 28, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Aug 28, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Aug 28, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 6, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 5, 2024 EX2G S SOU EXTENSION 2 GRANTED Loading...
Mar 5, 2024 EXT2 S SOU EXTENSION 2 FILED Loading...
Mar 5, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 28, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 26, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jul 26, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Jul 26, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 11, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 14, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 14, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 25, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 12, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 10, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jan 10, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jan 10, 2023 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Jan 10, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Aug 2, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 2, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 2, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 1, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 25, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 22, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Research and development of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, epilepsy, physical injury, stroke, cerebral aneurysm, traumatic brain injury, concussion, a tumor, cancer, inflammation, infection, ataxia, brain atrophy, spinal cord atrophy, multiple sclerosis, traumatic spinal cord injury, ischemic or hemorrhagic myelopathy (myelopathy), global ischemia, hypoxic ischemic encephalopathy, embolism, fibrocartilage embolism myelopathy, thrombosis, nephropathy, chronic inflammatory disease, meningitis, cerebral venous sinus thrombosis, retinal disease and other disease arising from neuronal damage; and testing, inspection, research or development of pharmaceutical preparations for gene therapy or small molecule treatment
First Use Anywhere: Mar 31, 2025
First Use in Commerce: Mar 31, 2025

Classification

International Classes
042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"ASTROCYTES TO NEURONS"